[Tissue engineered bone regeneration of periosteal cells using recombinant human bone morphogenetic protein 2 induce]
- PMID: 15759922
[Tissue engineered bone regeneration of periosteal cells using recombinant human bone morphogenetic protein 2 induce]
Abstract
Objective: To investigate bone regeneration of the cell-biomaterial complex using strategies of tissue engineering based on cells.
Methods: Hydroxyapatite/collagen (HAC) sandwich composite was produced to mimic the natural extracellular matrix of bone, with type I collagen serving as a template for apatite formation. A three-dimensional poly-porous scaffold was developed by mixing HAC with poly(L-lactic acid) (PLA) using a thermally induced phase separation technique (TIPS). The rabbit periosteal cells were treated with 500 ng/ml of recombinant human bone morphogenetic protein 2 (rhBMP-2), followed by seeded into pre-wet HAC-PLA scaffolds. Eighteen 3-month nude mice were implanted subcutaneously cell suspension (group A, n = 6), simple HAC-PLA scaffold (group B, n = 6) and cell-biomaterial complex (group C, n = 6) respectively.
Results: Using type I collagen to template mineralization of calcium and phosphate in solution, we get HAC sandwich composite, mimicking the natural bone both in composition and microstructure. The three dimensional HAC-PLA scaffold synthesized by TIPS had high porosity up to 90%, with pore size ranging from 50 microm to 300 microm. SEM examination proved that the scaffold supported the adhesion and proliferation of the periosteal cells. Histology results showed new bone formation 8 weeks after implantation in group C. The surface of group A was smooth without neoplasma. Fibrous tissue invasion occurred in group B and no bone and cartilage formations were observed.
Conclusion: The constructed tissue engineering bone has emerged as another promising alternative for bone repair.
Similar articles
-
A study on a tissue-engineered bone using rhBMP-2 induced periosteal cells with a porous nano-hydroxyapatite/collagen/poly(L-lactic acid) scaffold.Biomed Mater. 2006 Jun;1(2):56-62. doi: 10.1088/1748-6041/1/2/002. Epub 2006 Apr 6. Biomed Mater. 2006. PMID: 18460757
-
In vivo bone formation from human embryonic stem cell-derived osteogenic cells in poly(d,l-lactic-co-glycolic acid)/hydroxyapatite composite scaffolds.Biomaterials. 2008 Mar;29(8):1043-53. doi: 10.1016/j.biomaterials.2007.11.005. Epub 2007 Nov 26. Biomaterials. 2008. PMID: 18023477
-
Targeted delivery system for juxtacrine signaling growth factor based on rhBMP-2-mediated carrier-protein conjugation.Bone. 2006 Oct;39(4):825-36. doi: 10.1016/j.bone.2006.04.027. Epub 2006 Jun 16. Bone. 2006. PMID: 16782421
-
Critical aspects of tissue-engineered therapy for bone regeneration.Crit Rev Eukaryot Gene Expr. 2001;11(1-3):173-98. Crit Rev Eukaryot Gene Expr. 2001. PMID: 11693960 Review.
-
Periosteal cells in bone tissue engineering.Tissue Eng. 2003;9 Suppl 1:S45-64. doi: 10.1089/10763270360696978. Tissue Eng. 2003. PMID: 14511470 Review.
Cited by
-
High-fat and high-glucose microenvironment decreases Runx2 and TAZ expression and inhibits bone regeneration in the mouse.J Orthop Surg Res. 2019 Feb 18;14(1):55. doi: 10.1186/s13018-019-1084-2. J Orthop Surg Res. 2019. PMID: 30777111 Free PMC article.
-
Bone Regeneration Using Bone Morphogenetic Proteins and Various Biomaterial Carriers.Materials (Basel). 2015 Apr 15;8(4):1778-1816. doi: 10.3390/ma8041778. Materials (Basel). 2015. PMID: 28788032 Free PMC article. Review.